Meropenem-induced reduction in colistin susceptibility in Pseudomonas aeruginosa strain ATCC 27853

About authors

Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Tatiana A. Savinova
Ostrovityanova, 1, Moscow, 117997, Russia; moc.liamg@avonivasainat

About paper

Funding: the study was supported by the Russian Science Foundation (Project 20-15-00235).

Acknowledgements: the authors thank the Center of Precision Genome Editing and Genetic Technologies for Biomedicine of Pirogov Russian National Research Medical University for their advice on the methodology of the study.

Author contribution: Savinova TA — formal analysis of sequencing data, manuscript preparation; Bocharova YuA — methodology, formal analysis; Chaplin AV — formal analysis of sequencing data; Korostin DO — methodology, data validation; Shamina OV — methodology; Mayansky NA, Chebotar IV — concept; manuscript editing.

Received: 2021-12-27 Accepted: 2022-01-10 Published online: 2022-01-19

Antibiotic-resistant strains of Pseudomonas aeruginosa are a global threat to public health. The knowledge of mechanisms underlying antibiotic resistance is essential to counter P. aeruginosa infections. This study describes the phenomenon of meropenem-induced cross-resistance to colistin in the ATCC 27853 strain of P. aeruginosa. The study was conducted in the specimens of P. aeruginosa grown from the reference ATCC 27853 strain in the medium containing meropenem gradients. Susceptibility of the isolates to carbapenems and colistin was assessed using the agar dilution method; susceptibly to colistin was assessed using the broth microdilution method. A total of 93 P. Aeruginosa isolates were analyzed; of them two demonstrated reduced susceptibility to carbapenems (meropenem, imipenem) and colistin. Whole-genome sequencing of the isolates was performed on a MGISEQ-2000 platform. Missense mutations in the oprD and mexD genes and a nonsense mutation in the phoQ gene were detected. We conclude that exposure of P. aeruginosa to meropenem can lead to cross-resistance to colistin, a last resort drug for P. aeruginosa infections.